About

Vineet Laboratories Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹69 Cr

P/E

43.1×

P/B

1.5×

Dividend yield

0%

ROE

5.3%

ROCE

15.9%

Debt / equity

0.99

OPM

14.3%

EPS (TTM)

₹0.8

Book value

₹23.7

52-week high

₹47.9

52-week low

₹29.0

₹35.9+1.4%1Y

Beta

0.92

Moves with the index

Volatility (1y)

46%

Annualised, daily returns

RSI (14)

50.6

Neither overbought nor oversold

Rel. strength (1y)

-7.5%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -24.5% (3-yr avg)
−Profit declined 2.1% a year over the last 5 years
−Revenue shrank over the last 5 years (-24.6% a year)
−Weak interest coverage of 1.3×
−Low promoter holding of 6%
−Promoter holding fell 23.3 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

41/100

Business quality: 24
Growth: 43
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	243	191	212	151	75	59
COGS	198	146	172	114	70	39
Gross profit	45	46	40	37	5	21
	37	32	32	29	21	12
	8	13	8	7	-16	8
OPM %	3.4%	6.9%	3.6%	4.8%	-21.7%	14.3%
Depreciation	2	2	2	3	3	2
Interest	3	2	3	5	4	5
	0	0	0	0	2	1
Profit before tax	4	9	2	0	-21	2
Tax	2	3	1	-1	-1	0
Tax %	56.2%	29%	38.4%	-183.3%	-2.8%	9.6%
	2	7	1	1	-20	2
PAT margin %	0.7%	3.5%	0.6%	0.7%	-26.9%	2.7%
EPS (₹)	2.2	7.2	1.4	1.1	-21.9	1
EPS adjusted (₹)	—	—	1.4	1.1	-21.9	0.8
	0%	14%	0%	0%	—	—
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	9	9	9	19
Reserves	24	26	5	26
	31	44	40	45
	51	38	40	34
Total equity & liabilities	116	117	95	125
	27	27	25	24
CWIP	0	—	—	0
Investments	0	0	0	0
	89	90	69	100
Total assets	116	117	95	125

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-9	8	-10	-11	11	-12
	-8	-4	-7	0	-3	-1
	19	12	0	11	-8	30
Net cash flow	2	16	-16	-0	0	16
Free cash flow	-17	4	-17	-12	10	-13
CFO / Operating profit %	-106.9%	58.2%	-125.8%	-158.8%	—	-144.3%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	18.6%	23.9%	18.8%	24.4%	6.3%	35%
EBITDA margin %	3.4%	6.9%	3.6%	4.8%	-21.7%	14.3%
EBIT margin %	2.6%	5.9%	2.5%	3.1%	-25%	10.2%
PAT margin %	0.7%	3.5%	0.6%	0.7%	-26.9%	2.7%
Working capital
Receivable days	—	—	60	77	64	70
Inventory days	—	—	98	158	260	606
Payable days	—	—	74	103	175	240
NWC days	—	—	84	131	149	437
Leverage
Current ratio	—	—	1.17	1.16	0.91	1.47
Debt to EBITDA	—	—	4.06	6.15	—	5.35
Debt to equity	—	—	0.92	1.28	2.73	0.99
Interest coverage	2.5	5.3	1.6	1.1	-4.2	1.3
Asset turnover	—	—	1.83	1.29	0.79	0.48
Return ratios
Return on assets %	—	—	1.1%	0.9%	-21.4%	1.3%
Return on capital employed %	—	—	13.1%	12.5%	-55%	15.9%
Return on equity %	—	—	3.7%	3%	-137.8%	3.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	38.66%	37.55%	37.5%	37.5%	36.07%	35.85%	35.85%	29.26%	15.89%	12.46%	5.98%	5.98%
	0%	0.24%	0%	0%	0%	0%	0%	0%	0%	0%	0.36%	0.5%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	61.34%	62.21%	62.5%	62.5%	63.93%	64.15%	64.15%	70.74%	84.11%	87.54%	93.66%	93.52%
No. of shareholders	—	—	—	—	—	—	—	—	9,682	10,003	9,929	9,901

Promoter holding down 32.68 percentage points since Sep 2023.

6 disclosures

Person	Deal	Shares	Value	Holding	Filed
ALLURI RANGA RAJUPromoters	SellMarket Sale	25,000	₹9.9 L	1.92% → 1.65%	4 Oct 20257(2)
Satyanarayana Raju BhupathirajuPromoters	SellMarket Sale	22,726	₹8.15 L

146 deals · 6 Apr 2022 – 1 Oct 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
1 Oct 2026	SRIVENKATA SITA RAMA RAO TUMULA	Bulk	BSE	Buy	2,41,000	₹36.42	₹0.88 Cr
24 Sept 2026	GALAXY PRIME PRIVATE LIMITED	Bulk	BSE	Buy	5,00,000	₹35.32	₹1.77 Cr
24 Sept 2026	SUDHA MADHU SUDHAN REDDY	Bulk	BSE	Sell	1,00,000	₹35.33	₹0.35 Cr
24 Sept 2026	SANGATILEELAVINAYREDDY	Bulk	BSE	Sell	1,00,000	₹35.32	₹0.35 Cr
24 Sept 2026	KRISHNA REDDY MUTUKUNDU	Bulk	BSE	Sell	1,00,000	₹35.31	₹0.35 Cr
15 Sept 2026	DEREDDY VASANTHI	Bulk	BSE	Buy	1,30,000	₹36.38	₹0.47 Cr
15 Sept 2026	PALLOLIRAMACHANDRAREDDY	Bulk	BSE	Sell	1,28,340	₹36.40	₹0.47 Cr
21 Aug 2026	ARJUN AGGARWAL	Bulk	NSE	Sell	1,10,587	₹37.83	₹0.42 Cr
21 Aug 2026	SUJATA KUMARI JHA	Bulk	NSE	Buy	1,09,870	₹37.77	₹0.41 Cr
27 Apr 2026	MANCHURI MANOHAR REDDY	Bulk	NSE	Sell	1,49,573	₹38.38	₹0.57 Cr

1–10 of 146

1 / 15

Mr. DILIP VISHNU ACHAREKARNon-Executive - Independent Director-Chairperson
Mr. SATYANARAYANA RAJU BHUPATHIRAJUExecutive Director
Mr. RANGA RAJU ALLURINon-Executive - Non Independent Director
Mr. Premananda Reddy VennapusaNon - Executive Non -Independent Director
Ms. Jasmin Kunal TaylorNon - Executive Independent Director
Mr. Rajesh Kumar KathullaExecutive Director
Mr. Gaddam Venkata RamanaNon - Executive Non -Independent Director

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Vineet Laboratories Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

5

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Final dividend19 Sept 2022 · ex-date₹1

2

Board meeting to consider results25 Aug 2026
Board meeting to consider results15 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

13 announcementsExport CSV

30 Sept 2026, 8:24 pmCompany Update

Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors

Resignation of Statutory Auditors PDF

30 Sept 2026, 4:11 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

19 Sept 2026, 3:06 pmCompany Update

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Grant Of Extension Of Time By The Registrar Of Companies For Holding The 10St Annual General Meeting Of The Company

General PDF

29 Aug 2026, 5:53 pmResult

Results-Delay in Financial Results

Financial Results PDF

25 Aug 2026, 7:28 pmResult

Results-Delay in Financial Results

Financial Results PDF

25 Aug 2026, 7:12 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, August 25, 2026 As Required Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

Outcome of Board Meeting PDF

20 Aug 2026, 6:23 pmBoard Meeting

Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Exchange filing PDF

14 Aug 2026, 6:59 pmCompany Update

Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Monitoring Agency Report PDF

Date	Category	Subject	Filing
30 Sept 2026, 8:24 pm	Company Update Resignation of Statutory Auditors	Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors	PDF
30 Sept 2026, 4:11 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Vineet Laboratories Limited

Vineet Laboratories Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

2

Announcements

1

2

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Vineet Laboratories Limited

Vineet Laboratories Limited

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends1

Board meetings2

Announcements

Ratio timeline

Dividends1

Board meetings2

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

2

1

2